Literature DB >> 2040636

Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation.

J H Lawson1, K G Mann.   

Abstract

The activation of human coagulation factor IX by human tissue factor.factor VIIa.PCPS.Ca2+ (TF.VIIa.PCPS.Ca2+) and factor Xa.PCPS.Ca2+ enzyme complexes was investigated. Reactions were performed in a highly purified system consisting of isolated human plasma proteins and recombinant human tissue factor with synthetic phospholipid vesicles (PCPS: 75% phosphatidylcholine (PC), 25% phosphatidylserine (PS)). Factor IX activation was evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, [3H]factor IX activation peptide assay, colorimetric substrate thiobenzyl benzyloxycarbonyl-L-lysinate (Z-Lys-SBzl) hydrolysis, and specific incorporation of a fluorescent peptidyl chloromethyl ketone. Factor IX activation by the TF.VIIa.PCPS.Ca2+ enzyme complex was observed to proceed through the obligate non-enzymatic intermediate species factor IX alpha. The simultaneous activation of human coagulation factors IX and X by the TF.VIIa.PCPS.Ca2+ enzyme complex were investigated. When factors IX and X were presented to the TF.VIIa complex, at equal concentrations, it was observed that the rate of factor IX activation remained unchanged while the rate of factor X activation slowed by 45%. When the proteolytic cleavage products of this reaction were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, it was observed that the intermediate species factor IX alpha was generated more rapidly when factor X was present in the reaction mixture. When factor IX was treated with factor Xa.PCPS in the presence of Ca2+, it was observed that factor IX was rapidly converted to factor IX alpha. The activation of factor IX alpha by the TF.VIIa.PCPS.Ca2+ complex was evaluated, and it was observed that factor IX alpha was activated more rapidly by the TF.VIIa.PCPS.Ca2+ complex than was factor IX itself. These data suggest that factors IX and X, when presented to the TF.VIIa.PCPS.Ca2+ enzyme complex, are both rapidly activated and that factor Xa, which is generated in the initial stages of the extrinsic pathway, participates in the first proteolytic step in the activation of factor IX, the generation of factor IX alpha.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2040636

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Probing the structural changes in the light chain of human coagulation factor VIIa due to tissue factor association.

Authors:  L Perera; T A Darden; L G Pedersen
Journal:  Biophys J       Date:  1999-07       Impact factor: 4.033

Review 2.  Tissue factor controversies.

Authors:  Kenneth G Mann; Jolanta Krudysz-Amblo; Saulius Butenas
Journal:  Thromb Res       Date:  2012-03-07       Impact factor: 3.944

3.  Taking the thrombin "fork".

Authors:  Kenneth G Mann
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-07       Impact factor: 8.311

4.  Exosite-mediated substrate recognition of factor IX by factor XIa. The factor XIa heavy chain is required for initial recognition of factor IX.

Authors:  Taketoshi Ogawa; Ingrid M Verhamme; Mao-Fu Sun; Paul E Bock; David Gailani
Journal:  J Biol Chem       Date:  2005-04-13       Impact factor: 5.157

5.  Influence of mutations in tissue factor on the fine specificity of macromolecular substrate activation.

Authors:  S Dittmar; W Ruf; T S Edgington
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

6.  Plasmin-mediated proteolysis of human factor IXa in the presence of calcium/phospholipid: Conversion of procoagulant factor IXa to a fibrinolytic enhancer.

Authors:  Amy E Schmidt; Kanagasabai Vadivel; Julian Whitelegge; Satya Paul Bajaj
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

Review 7.  The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome.

Authors:  John Paul Vavalle; Mauricio G Cohen
Journal:  Future Cardiol       Date:  2012-03-15

8.  New developments in anticoagulation for atrial fibrillation.

Authors:  M Haris U Usman; Lawrence A Notaro; Harsh Patel; Michael D Ezekowitz
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-09

Review 9.  Thrombin inhibitors from different animals.

Authors:  A M Tanaka-Azevedo; K Morais-Zani; R J S Torquato; A S Tanaka
Journal:  J Biomed Biotechnol       Date:  2010-10-04

10.  First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa.

Authors:  D Zhong; K J Smith; J J Birktoft; S P Bajaj
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.